Vor Biopharma Inc expected to post a loss of 38 cents a share - Earnings Preview

Vor Biopharma

08/05/2023 12:35

* Vor Biopharma Inc  VOR.OQ   VOR.O  is expected to show no
change
in quarterly revenue when it reports  results on May 10
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Vor Biopharma Inc
is for
a loss of 38 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vor
Biopharma Inc
is $16.75​, above​ its last closing price of $3.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.47       -0.60      -0.52     Beat    13.7
 Sep. 30 2022  -0.60       -0.61      -0.63     Missed  -3.7
 Jun. 30 2022  -0.66       -0.66      -0.58     Beat    11.9​
 Mar. 31 2022  -0.52       -0.51      -0.61     Missed  -18.9
 ​​Dec.        -0.52       -0.57      -0.48     Beat    15.2
 31 2021                                                
 Sep. 30 2021  -0.61       -0.62      -0.50     Beat    19.7​
 Jun. 30 2021  -0.47       -0.50      -0.50     Met     0.5
 Mar. 31 2021  -0.63       -0.62      -0.67     Missed  -7.5
 This summary was machine generated May 8 at 11:35 GMT.  All
figures in US dollars  unless otherwise stated